AstraZeneca announced a $50 billion investment plan to enhance its manufacturing and research operations in the United States through 2030. The expansion includes building the company’s largest-ever facility in Virginia, focusing on small molecules, peptides, and oligonucleotides related to metabolic and weight management drugs. The investment aims to increase AstraZeneca’s U.S. revenue share from 42% to 50%, supporting the goal of launching 20 new medicines by decade-end and driving global growth.